Chih-Hsin Yang - JoVE Visualize

Showing results (291-300 of 324) with videos related to

Pageof 33

Sort By:

Lung Cancer (Amsterdam, Netherlands)|April 29, 2025

Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subsetByoung Chul Cho, Hidetoshi Hayashi, Jong-Seok Lee, et al.

Cancer Discovery|April 11, 2022

Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsMengzhao Wang, James Chih-Hsin Yang, Paul L Mitchell, et al.

Clinical Lung Cancer|September 23, 2022

Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic ConsiderationsMyung-Ju Ahn, Marvin Jonne L Mendoza, Nick Pavlakis, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 22, 2023

Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset AnalysisRoss A Soo, Byoung Chul Cho, Joo-Hang Kim, et al.

Proceedings of the National Academy of Sciences of the United States of America|July 10, 2012

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1Kadoaki Ohashi, Lecia V Sequist, Maria E Arcila, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2023

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301Byoung Chul Cho, Myung-Ju Ahn, Jin Hyoung Kang, et al.

Nature Medicine|July 10, 2023

Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim resultsMartin Gutierrez, Wei-Sen Lam, Matthew D Hellmann, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2023

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 TrialKoichi Goto, Yasushi Goto, Toshio Kubo, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2023

CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung CancerPasi A Jänne, David Planchard, Kunihiko Kobayashi, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 11, 2015

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I MutationsChao-Hua Chiu, Cheng-Ta Yang, Jin-Yuan Shih, et al.

Pageof 33

Showing results (291-300 of 324) with videos related to

Sort By:

Pageof 33

Lung Cancer (Amsterdam, Netherlands)|April 29, 2025

Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subsetByoung Chul Cho, Hidetoshi Hayashi, Jong-Seok Lee, et al.

Cancer Discovery|April 11, 2022

Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsMengzhao Wang, James Chih-Hsin Yang, Paul L Mitchell, et al.

Clinical Lung Cancer|September 23, 2022

Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic ConsiderationsMyung-Ju Ahn, Marvin Jonne L Mendoza, Nick Pavlakis, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 22, 2023

Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset AnalysisRoss A Soo, Byoung Chul Cho, Joo-Hang Kim, et al.

Proceedings of the National Academy of Sciences of the United States of America|July 10, 2012

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1Kadoaki Ohashi, Lecia V Sequist, Maria E Arcila, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2023

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301Byoung Chul Cho, Myung-Ju Ahn, Jin Hyoung Kang, et al.

Nature Medicine|July 10, 2023

Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim resultsMartin Gutierrez, Wei-Sen Lam, Matthew D Hellmann, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2023

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 TrialKoichi Goto, Yasushi Goto, Toshio Kubo, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2023

CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung CancerPasi A Jänne, David Planchard, Kunihiko Kobayashi, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 11, 2015

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I MutationsChao-Hua Chiu, Cheng-Ta Yang, Jin-Yuan Shih, et al.

Pageof 33